Founded in 2002, ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company with headquarters in San Diego, California, and with world-class manufacturing operations in Hangzhou, China. ACEA pioneers in development and commercialization of innovative cell analysis instrumentation for life sciences, and is also engaged in drug discovery and pharmaceutical development. ACEA's xCELLigence impedance-based, label-free, real-time cell analysis systems and NovoCyte™ benchtop flow cytometers are used in preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, and basic academic research. More than 1,700 of these instruments have been placed globally, leading to >700 peer reviewed publications from both academia and the pharmaceutical industry in diverse applications spanning everything from cancer immunotherapy and cardiotoxicity to chemotactic migration and GPCR inhibition. With the xCELLigence and NovoCyte technology platforms now well established, ACEA continues to work closely with scientists around the world to bring new innovative solutions to the R&D and health care industries.

Key Contact